Eucalyptus accuses Australian medical regulators of damaging patient outcomes with sudden telehealth guideline changes.

Eucalyptus, a technology start-up, accuses Australian medical regulators of damaging patient outcomes by making drastic changes to telehealth prescribing guidelines without sufficient data. The company claims it complies with Medical Board guidelines and that its platform offers detailed pre-consultation questionnaires for users. Eucalyptus CEO Tim Doyle criticizes the traditional GP-patient model as outdated in modern society.

March 17, 2024
4 Articles